A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

American Journal of Gastroenterology

Volumn 96, Issue 2, 2001, Pages 519-525

  Caldwell, Stephen H ^a   Hespenheide, Elizabeth E ^a   Redick, Jan A ^a   Iezzoni, Julia C ^a   Battle, Emily H ^a   Sheppard, Bonnie L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LEPTIN; LIGAND; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; ELECTRON MICROSCOPY; FATTY LIVER; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HYPERINSULINEMIA; LIVER BIOPSY; LIVER MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; STEATOSIS; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; CHROMANS; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; PILOT PROJECTS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035120396     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02346-7     Document Type: Article

References (53)

1. Troglitazone (CS-045): A new diabetic agent
2. Thiazolidinediones: Tools for the study of metabolic syndrome X
3. Medical significance of peroxisome proliferator-activated receptors
4. Pharmacologic therapy for type 2 diabetes
5. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM patients
6. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
7. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling
8. Trogliazone increases the number of small adipocytes without the change in white adipose tissue mass in obese Zucker rats
9. PPAR-γ: Adipogenic regulator and thiazolizinedione receptor
10. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
11. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
12. Effects of troglitazone and metformin on glucose and lipid metabolism
13. Fatty acid-induced beta cell apoptosis: A link between obesity and diabetes
14. Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle
15. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes
16. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling
17. Thizolidinediones: A new class of antidiabetic drugs
18. Insulin action in the normal and polycystic ovary
19. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
20. Nonalcoholic steatohepatitis
21. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance
22. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
23. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
24. Cryptogenic cirrhosis - A disappearing disorder?
25. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds
26. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
27. Hepatic subcapsular steatosis in a patient with insulin dependent diabetes receiving dialysis
28. Altered C-peptide/insulin molar ratios in obese patients with fatty liver
29. Mitochondrial abnormalities in non-alcoholic steatohepatitis
30. Activity of the mitochondrial respiratory chain enzymes is decreased in the liver of patients with non-alcoholic steatohepatitis
31. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver
32. Opening of mitochondrial permeability transition pores causes mitochondrial distension and outer membrane rupture in FAS-mediated hepatic apoptosis
33. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: A pilot study
34. Metformin treatment in patients with nonalcoholic steatohepatitis
35. Hepatic effects of dietary weight loss in morbidly obese subjects
36. Nonalcoholic steatohepatitis
37. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
38. Troglitazone-induced hepatic failure leading to liver transplantation
39. Severe cholestatic hepatitis from troglitazone in a patient with non-alcoholic steatohepatitis and diabetes mellitus
40. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
41. Hepatic dysfunction associated with troglitazone
42. Diabetes drug withdrawn after reports of hepatic events
43. Prevalence of overweight and weight gain in the United States
44. Guidelines for healthy weight
45. Nonalcoholic steatohepatitis: A proposal for grading and staging the histologic lesions
46. Optical diffraction studies of crystalline structures in electron micrographs. II. Crystalline inclusions in mitochondria of human hepatocytes
47. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease
48. Reduced hepatocellular turnover in patients chronically infected with hepatitis C virus and persistently normal ALT levels
49. TUNEL-positive hepatocytes in alcoholic liver disease
50. Higher rate for poor metabolizers of cytochrome P450 2C19 in patients with liver injury by trogliazone-analysis of allelic variations
51. Hepatic failure in a patient taking rosiglitazone
52. Hepatocellular injury in a patient receiving rosiglitazone